Primary Site >> Pancreatic Cancer

Gene >> ERCC2

  • 2012
  • 2013
  • 2015
  • 2016
  • 2017
Ref: A phase II trial of erlotinib in combination with gemcitabine and capecitabine in previously untreated metastatic/recurrent pancreatic cancer: combined analysis with translational research.
PMID: 21404106
Ref: Prognostic factors in gemcitabine-cisplatin polychemotherapy regimens in pancreatic cancer: XPD-Lys751Gln polymorphism strikes back.
PMID: 23390054
Ref: Association of single nucleotide polymorphisms of DNA repair genes in NER pathway and susceptibility to pancreatic cancer.
PMID: 26617894
Ref: Role of single nucleotide polymorphisms of DNA repair genes in susceptibility to pancreatic cancer in Chinese population.
PMID: 27050953
Ref: Association between ERCC1 and ERCC2 gene polymorphisms and susceptibility to pancreatic cancer.
PMID: 27051038
Ref: Association between ERCC2 Lys751Gln polymorphism and the risk of pancreatic cancer, especially among Asians: evidence from a meta-analysis.
PMID: 28223548